InvestorsHub Logo
Followers 11
Posts 1703
Boards Moderated 0
Alias Born 02/08/2002

Re: None

Friday, 02/07/2020 5:15:49 PM

Friday, February 07, 2020 5:15:49 PM

Post# of 3699
Last patient in current study should get his/her final dose end of Feb. Need some news to get us out of this current channel. This PR dated 01/28.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125. This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences’ investigational drug to treat Alzheimer’s disease. A total of 64 patients were enrolled in this study and top-line results are expected mid-year 2020.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SAVA News